Nasdaq-Listed Windtree Therapeutics, a clinical-stage biotech, has signed a securities purchase agreement worth $60 million. The transaction, led by Build and Build Corp, could grow to $200 million with future follow-on subscriptions. Windtree Announces $200M BNB Treasury Strategy According to a press release, Windtree Therapeutics, has entered into a securities purchase agreement led by Build
The post Just In: Nasdaq Listed Windtree Launches BNB Treasury With $200M Investment appeared first on CoinGape.
